Latest News and Press Releases

Arcutis announced today that it will report Q2 2025 financial results and provide a business update on Aug 6, 2025 after the U.S. financial markets close.

WESTLAKE VILLAGE, Calif., July 03, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in...

The American Academy of Dermatology (AAD) provided evidence-based recommendation for the use of ZORYVE® (roflumilast) cream 0.15% in adults with AD

The first child has been enrolled in Phase 2 INTEGUMENT-INFANT study evaluating the safety and tolerability of investigational ZORYVE cream for AD

WESTLAKE VILLAGE, Calif., June 06, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in...

Arcutis to present five posters at the 2025 Revolutionizing Atopic Dermatitis (RAD) Conference, taking place in Nashville, TN, from June 6-7, 2025.

Arcutis today announced that management will participate in the Goldman Sachs 46th Annual Global Healthcare Conference, taking place June 9-11, 2025.

FDA has approved the supplemental New Drug Application (sNDA) for ZORYVE® foam 0.3% for the treatment of plaque psoriasis

Arcutis announced the publication of 14 consensus statements from the Genital Psoriasis Wellness Consortium on the impact of genital psoriasis on patients.

JAMA Dermatology published the positive results from a pivotal Phase 3 study evaluating the efficacy and safety of ZORYVE® (roflumilast) foam 0.3%